Publication:
Anti Phospholipid Antibodies in Turkish Children with Thrombosis

dc.contributor.authorTavil, Betul
dc.contributor.authorOzyurek, Emel
dc.contributor.authorGumruk, Fatma
dc.contributor.authorCetin, Mualla
dc.contributor.authorGurgey, Aytemiz
dc.date.accessioned2020-06-21T15:19:57Z
dc.date.available2020-06-21T15:19:57Z
dc.date.issued2007
dc.departmentOMÜen_US
dc.department-tempHacettepe Univ, Fac Med, Pediat Hematol Unit, TR-06100 Ankara, Turkey -- Samsun 19 Mayis Univ, Fac Med, Pediat Hematol Unit, Samsun, Turkey --en_US
dc.description.abstractAntiphospholipid syndrome is a systemic disorder characterized by arterial and/or venous thrombosis, thrombocytopenia, recurrent fetal loss, and presence of anti phospholipid antibodies (APA). The importance of APA in Turkish children with thrombosis is unknown. This study aimed to evaluate the frequency of APA positivity, associated risk factors other than APA, and outcome in children with APA and thrombosis. The presence of APA was investigated in 138 children presenting for evaluation of thrombosis; other prothrombotic risk factors were also studied. The frequency of APA positivity among 138 children was 11.6% (16/138). The mean age of these 16 children (110 female, 62.5%) was 9.57 +/- 4.59 years (range, 2.5-18.0 years). The mean follow-up period was 31.7 +/- 21.7 months (range, 5 - 60 months). Recurrence was observed during follow-up in two patients (12.5%). Ten patients (62.5%) had arterial thrombosis, five patients (31.3%) venous thrombosis, and one patient (6.3%) purpura fulminans. Among the thrombotic children with APA, 11 (68.8%) had more than one prothrombotic risk factor other than circulating APA [five patients (31.3%) had two risk factors, two patients (12.5%) had three, and four patients (25.0%) had four]. Five patients (31.3%) had no additional risk factors. APA should be tested in all children with thrombosis, especially those with arterial thrombosis.en_US
dc.identifier.doi10.1097/MBC.0b013e32809cc95a
dc.identifier.endpage352en_US
dc.identifier.issn0957-5235
dc.identifier.issue4en_US
dc.identifier.pmid17473576
dc.identifier.startpage347en_US
dc.identifier.urihttps://doi.org/10.1097/MBC.0b013e32809cc95a
dc.identifier.urihttps://hdl.handle.net/20.500.12712/19942
dc.identifier.volume18en_US
dc.identifier.wosWOS:000246795200009
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.journalBlood Coagulation & Fibrinolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiphospholipid Antibodiesen_US
dc.subjectAnti Phospholipid Syndromeen_US
dc.subjectThrombosisen_US
dc.titleAnti Phospholipid Antibodies in Turkish Children with Thrombosisen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files